{"analyses":[{"ciLowerLimit":"0.25","ciNumSides":"TWO_SIDED","ciPctValue":"98","ciUpperLimit":"1.69","groupDescription":"The Bayesian analyses below include posterior mean of Hazard ratio, and credible intervals instead of confidence intervals.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"The posterior probability treatment difference is 0.864","paramType":"Posterior Mean Hazard Ratio","paramValue":"0.69","statisticalMethod":"Bayesian hierarchical model"}],"classes":[{"categories":[{"measurements":[{"comment":"The posterior median = 5.69, 98% credible interval (3.20 to 10.01)","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The posterior median = 3.73, 98% credible interval (1.76 to 8.29)","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the date of investigator-determined objective progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause in the absence of disease progression. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later). The posterior median and 98% credible interval were estimated using Bayesian analysis. Data are presented as the posterior median with 98% credible interval.","dispersionType":"98% Confidence Interval","groups":[{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Ramucirumab administered intravenously at a dose of 12 mg/kg as a one-hour infusion on days 1 and 15.\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG000","title":"Ramucirumab + Cyclophosphamide + Vinorelbine"},{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG001","title":"Cyclophosphamide + Vinorelbine"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who received at least one dose of study drug (including the censored participants). Number of participants censored in Ramucirumab + Cyclophosphamide + Vinorelbine = 4, Cyclophosphamide + Vinorelbine = 2.","reportingStatus":"POSTED","timeFrame":"Randomization to Objective Progression or Death Due to Any Cause (Up To 23 Months)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}